Thromboembolic Diseases Background information for medical media outside the US only This selection gives an overview on background material for Thromboembolic Diseases available on the Boehringer Ingelheim corporate website.

Press Release

• 09 June 2008Boehringer Ingelheim announces first positive health technology assessments for novel oral anticoagulant Pradaxa® (dabigatran etexilate)
• 27 March 2008Novel oral anticoagulant Pradaxa® (dabigatran etexilate) approved by the European Commission (for medical media, outside the US only)
• 17 January 2008Boehringer Ingelheim announces enrolment completion of the largest atrial fibrillation outcomes trial - The RE-LY™ Study
• press release archive

Documents

• Fact sheet: Dabigatran Etexilate - PDF (63 KB)
• Fact sheet: Dabigatran Etexilate - A Breakthrough in Anticoagulation - PDF (55 KB)
• Backgrounder: Boehringer Ingelheim at a glance - PDF (2,2 MB)
• Backgrounder: Dabigatran Etexilate - A brief history - PDF (35 KB)
• Backgrounder: Venous Thromboembolism (VTE) - PDF (51 KB)
• Glossary: Thromboembolic Diseases - PDF (42 KB)
• Annual Report 2007: Page 37 - PDF (4.9 MB)